ARTICLE | Emerging Company Profile
Apros: Engineering tissue-targeted TLR agonists
Emerging Company Profile: Apros is developing a pipeline of five TLR7 agonists targeting different tissues
February 5, 2021 1:04 AM UTC
Apros is developing a suite of tissue-targeted TLR7 agonists for indications ranging from cancer to infectious disease that aim to avoid systemic toxicities that have plagued the drug class.
Lead candidate APR003, a TLR7 agonist designed to home to the liver and gastrointestinal tissue, entered Phase I testing this week to treat patients with unresectable colorectal cancer with malignant liver lesions...